Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Buoyed by the success of cadonilimab and ivonescimab the Chinese group takes two more bispecific MAbs into human trials.
After a rollercoaster existence Cellular Biomedicine Group has a new name, and new deals with AstraZeneca and J&J.
MorphoSys, Blueprint and Syndax celebrate a successful ASH; Cogent not so much.
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
The group highlights safety and manufacturability, as well as efficacy, but investors apparently have doubts.
Competitors struggle, while MorphoSys investors see a path forward for pelabresib after all.